Amel Arnaout

3.8k total citations
20 papers, 218 citations indexed

About

Amel Arnaout is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Epidemiology. According to data from OpenAlex, Amel Arnaout has authored 20 papers receiving a total of 218 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Surgery and 3 papers in Epidemiology. Recurrent topics in Amel Arnaout's work include Diabetes Treatment and Management (5 papers), Pituitary Gland Disorders and Treatments (4 papers) and Diabetes and associated disorders (3 papers). Amel Arnaout is often cited by papers focused on Diabetes Treatment and Management (5 papers), Pituitary Gland Disorders and Treatments (4 papers) and Diabetes and associated disorders (3 papers). Amel Arnaout collaborates with scholars based in Canada, United Kingdom and United States. Amel Arnaout's co-authors include Moeber Mahzari, Janine Malcolm, Dora Liu, Heather Lochnan, Mark S. Freedman, Ehab Youseif, Subodh Verma, Tayyab Khan, Mohamed Hassanein and Robyn L. Houlden and has published in prestigious journals such as SHILAP Revista de lepidopterología, Diabetes and Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

In The Last Decade

Amel Arnaout

18 papers receiving 214 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amel Arnaout Canada 7 86 75 44 38 35 20 218
Catharina Bullmann Germany 8 129 1.5× 48 0.6× 45 1.0× 34 0.9× 12 0.3× 13 269
В. В. Фадеев Russia 8 126 1.5× 21 0.3× 26 0.6× 9 0.2× 30 0.9× 86 232
Sinan Tanyolaç Türkiye 7 100 1.2× 39 0.5× 45 1.0× 18 0.5× 36 1.0× 11 264
Izumi Miki Japan 9 44 0.5× 41 0.5× 66 1.5× 7 0.2× 51 1.5× 23 296
Alban Fabre France 10 130 1.5× 33 0.4× 31 0.7× 14 0.4× 126 3.6× 11 441
Süheyla Görar Türkiye 11 110 1.3× 38 0.5× 49 1.1× 10 0.3× 15 0.4× 26 327
Ertuğrul Taşan Türkiye 11 149 1.7× 54 0.7× 52 1.2× 6 0.2× 34 1.0× 31 307
Karel David Belgium 9 71 0.8× 30 0.4× 56 1.3× 9 0.2× 31 0.9× 23 256
Aniceto Charro Spain 9 143 1.7× 66 0.9× 100 2.3× 16 0.4× 21 0.6× 24 310
Muzaffer Temür Türkiye 11 126 1.5× 46 0.6× 37 0.8× 23 0.6× 28 0.8× 46 398

Countries citing papers authored by Amel Arnaout

Since Specialization
Citations

This map shows the geographic impact of Amel Arnaout's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amel Arnaout with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amel Arnaout more than expected).

Fields of papers citing papers by Amel Arnaout

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amel Arnaout. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amel Arnaout. The network helps show where Amel Arnaout may publish in the future.

Co-authorship network of co-authors of Amel Arnaout

This figure shows the co-authorship network connecting the top 25 collaborators of Amel Arnaout. A scholar is included among the top collaborators of Amel Arnaout based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amel Arnaout. Amel Arnaout is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arnaout, Amel, et al.. (2024). Hypoglycemia Unawareness and Recurrent Severe Hypoglycemia in an Individual With Type 1 Diabetes Mellitus on Insulin. AACE Clinical Case Reports. 10(3). 101–104.
2.
Arnaout, Amel, et al.. (2023). Effects of Prediabetes on Long-term Risk of Developing Cardiac Events in Patients Presenting With Acute Coronary Syndrome. Canadian Journal of Diabetes. 47(6). 490–496. 3 indexed citations
3.
Arnaout, Amel, et al.. (2021). Comparing the content of traditional faxed consultations to eConsults within an academic endocrinology clinic. Journal of Clinical & Translational Endocrinology. 24. 100260–100260. 5 indexed citations
4.
Malcolm, Janine, et al.. (2021). Real-World Patient Experience of Long-Term Hybrid Closed-Loop Insulin Pump Use. Canadian Journal of Diabetes. 45(8). 750–756.e3. 10 indexed citations
5.
Beamish, Paul W., et al.. (2021). Patient Perspectives on Virtual Care for Diabetes Management in the Era of COVID-19. Canadian Journal of Diabetes. 45(7). S2–S2.
6.
Mazer, C. David, Amel Arnaout, Kim A. Connelly, et al.. (2019). Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischarge. Current Opinion in Cardiology. 35(2). 178–186. 6 indexed citations
7.
Dong, Ying, et al.. (2019). Does a Canadian diabetes curriculum work for future physicians in China? Lessons from the Ottawa Shanghai Joint School of Medicine. SHILAP Revista de lepidopterología. 10(1). e5–12. 1 indexed citations
8.
Bajaj, Harpreet S., Amel Arnaout, Mohamed Hassanein, et al.. (2018). Diabetes Canada Position Statement for People With Types 1 and 2 Diabetes Who Fast During Ramadan. Canadian Journal of Diabetes. 43(1). 3–12. 38 indexed citations
9.
Arnaout, Amel, et al.. (2018). Effect of Preadmission Diabetes Intervention (PREHAB) on Postoperative Patient Outcomes in Cardiac Surgery. Diabetes. 67(Supplement_1). 1 indexed citations
10.
Li, Tony, Fahad Alkherayf, Janine Malcolm, et al.. (2018). Clinical Characteristics and Outcomes of Patients Treated for Acromegaly at a Tertiary Care Hospital. Canadian Journal of Diabetes. 42(5). S38–S38. 1 indexed citations
11.
Arnaout, Amel, et al.. (2018). Case Report of Bilateral Pheochromocytomas due to a Novel Max Mutation in a Patient Known to have a Pituitary Prolactinoma. AACE Clinical Case Reports. 4(6). e453–e456. 12 indexed citations
12.
Malcolm, Janine, et al.. (2017). Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis. Canadian Journal of Diabetes. 41(5). 499–503. 32 indexed citations
13.
Clemons, Mark, Anil A. Joy, John Hilton, et al.. (2017). Physician "Out of Office" Alert: Does It Work?. Current Oncology. 24(3). 176–179. 2 indexed citations
14.
Li, Jennifer, et al.. (2016). SGLT2-Inhibitor Use Associated with Euglycemic Ketoacidosis: A Case Series. Canadian Journal of Diabetes. 40(5). S37–S38. 2 indexed citations
15.
Mahzari, Moeber, Amel Arnaout, & Mark S. Freedman. (2015). Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 42(5). 284–291. 17 indexed citations
16.
Mazzarello, Sasha, Mark Clemons, Carmel Jacobs, Amel Arnaout, & Michael Fralick. (2015). Publishing Clinical Research: Ten Pearls for Oncology Trainees and Junior Oncologists. Current Oncology. 22(1). 1–5. 4 indexed citations
17.
Mahzari, Moeber, Dora Liu, Amel Arnaout, & Heather Lochnan. (2015). Immune Checkpoint Inhibitor Therapy Associated Hypophysitis. Clinical Medicine Insights Endocrinology and Diabetes. 8. CMED.S22469–CMED.S22469. 38 indexed citations
18.
Druce, Irena, et al.. (2014). Assessment of Care of Patients with Pituitary Adenoma at One Canadian Tertiary Care Centre. Canadian Journal of Diabetes. 38(5). S3–S3. 1 indexed citations
19.
20.
Amon, Michael, et al.. (1999). Stability of the Bax (G)8 microsatellite in localized prostatic adenocarcinoma.. PubMed. 6(5). 853–858. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catharina Bullmann Breakdown of academic impact, for papers by В. В. Фадеев Breakdown of academic impact, for papers by Sinan Tanyolaç Breakdown of academic impact, for papers by Izumi Miki Breakdown of academic impact, for papers by Alban Fabre Breakdown of academic impact, for papers by Süheyla Görar Breakdown of academic impact, for papers by Ertuğrul Taşan Breakdown of academic impact, for papers by Karel David Breakdown of academic impact, for papers by Aniceto Charro Breakdown of academic impact, for papers by Muzaffer Temür
Rankless by CCL
2026